Peter Blume-Jensen - Feb 21, 2025 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
President and CEO, Director
Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact for Peter Blume-Jensen
Stock symbol
ACRV
Transactions as of
Feb 21, 2025
Transactions value $
-$110,268
Form type
4
Date filed
2/25/2025, 04:09 PM
Previous filing
Feb 19, 2025
Next filing
Mar 4, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Tax liability -$110K -19.9K -0.86% $5.54 2.29M Feb 21, 2025 Direct F1, F2
holding ACRV Common Stock 316K Feb 21, 2025 See Footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
F2 These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
F3 These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.